Your search returned 5 results.

Results
	1.	Lower skin cancer risk in women with higher body mass index: the women's health initiative observational study. MedStar authors: Aroda, Vanita R PMID: 24042260 Year: 2013 Citation: Cancer Epidemiology, Biomarkers & Prevention. 22(12):2412-5, 2013 Dec. Institution: MedStar Health Research Institute Medline publication type: Journal Article Research Support, N.I.H., Extramural Form of publication: Journal Article All authors: Aroda V, Desai M, Henderson MT, Hernandez-Boussard T, Kubo J, McTiernan A, Sims ST, Stefanick ML, Tang JY, Thomas F DOI: http://dx.doi.org/10.1158/1055-9965.EPI-13-0647 Add to cart (remove)
	2.	Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial. MedStar authors: Aroda, Vanita R PMID: 31359368 Year: 2019 Citation: Advances in Therapy. 36(9):2310-2326, 2019 09. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Bailey TS, Blonde L, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M DOI: https://dx.doi.org/10.1007/s12325-019-01033-1 Add to cart (remove)
	3.	Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors: Aroda, Vanita R PMID: 28386990 Year: 2017 Citation: Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C DOI: https://dx.doi.org/10.1111/dom.12961 Add to cart (remove)
	4.	Steroid Sex Hormones, Sex Hormone-Binding Globulin, and Diabetes Incidence in the Diabetes Prevention Program. MedStar authors: Aroda, Vanita R PMID: 26200237 Year: 2015 Citation: Journal of Clinical Endocrinology & Metabolism. 100(10):3778-86, 2015 Oct. Institution: MedStar Health Research Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Aroda VR, Barrett-Connor E, Christophi CA, Diabetes Prevention Program, Edelstein SE, Florez JC, Goldberg RB, Kahn SE, Kim C, Knowler WC, Labrie F, Mather KJ DOI: http://dx.doi.org/10.1210/jc.2015-2328 Add to cart (remove)
	5.	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors: Aroda, Vanita R PMID: 27650977 Year: 2016 Citation: Diabetes Care. 39(11):1972-1980, 2016 Nov Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C DOI: https://dx.doi.org/10.2337/dc16-1495 Add to cart (remove)

Powered by Koha